← Back to Search

Other

NoNO-42 for Acute Ischemic Stroke Treatment

Phase 1

Recruiting

Research Sponsored by NoNO Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 28 days

Awards & highlights

Study Summary

This trial is testing the safety, tolerability and how the body absorbs a new drug, NoNO-42, in healthy adults. Participants will be monitored for 24 hours after taking the drug.

Eligible Conditions

First-In-Human Study for Acute Ischemic Stroke Treatment

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 28 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~28 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Frequency of AEs, abnormal laboratory findings and abnormal vital signs

Secondary outcome measures

Pharmacokinetics of NoNO-42 following administration of a single ascending IV dose

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: NoNO-42Experimental Treatment1 Intervention

A single intravenous infusion weight-based dose of NoNO-42 administered over 10±1 minute

Group II: PlaceboPlacebo Group1 Intervention

A volume of 0.9% normal saline matching the volume required for a weight-based dosing of NoNO-42, administered as a single 10±1 minute intravenous infusion.

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

NoNO Inc.Lead Sponsor

5 Previous Clinical Trials

2,672 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research open to participants aged 25 or older?

"This study specifies that only participants aged between 18 and 60 will be accepted. However, there are 7 trials for minors and 334 trials specifically designed to serve elderly patients."

Answered by AI

What potential harm can individuals incur from exposure to NoNO-42?

"The safety of NoNO-42 is estimated at 1 due to its Phase 1 trial status, suggesting that only limited data has been collected about the drug's efficacy and security."

Answered by AI

Are new participants being enrolled in this experiment currently?

"Affirmative. Per the information posted on clinicaltrials.gov, this medical study initiated recruitment on November 22nd 2022 and is still in search of 44 participants from a single centre."

Answered by AI

What criteria must one meet to be admitted into this research project?

"In order to be eligible for this trial, applicants must meet the following criteria: supply a valid and dated informed consent form; agree to adhere faithfully to study protocols; have attained 18 years of age but not yet reached 60; have a BMI spanning from 18.5 kg/m2 up to 30.0 kg/m2 inclusive; weigh no more than 120kgs in total body mass; possess adequate bilateral venous access that can support IV infusions as judged by investigators or their delegates. This first-in-human study aims at assessing the safety of a new drug targeting acute ischemic stroke with 44 participants needed overall"

Answered by AI

How many individuals are currently receiving treatment in this experiment?

"Correct. Clinicaltrials.gov records demonstrate that recruitment for this medical study is ongoing, having been posted on November 22nd 2022 and last updated on December 1st 2022. Forty-four participants are being sought to take part at a single location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Phase 1 Study to Evaluate Safety and Tolerability of NoNO-42 in Healthy Adults

2022. "A Phase 1 Study to Evaluate Safety and Tolerability of NoNO-42 in Healthy Adults". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05636306.